The consensus price target hints at a 101.1% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.